AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10072025 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-thiopental combination
Number of subjects: 150
Study 10072025 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-thiopental combination
Number of subjects: 150
Study 10072025 — intervention group
Group type: COMPARATOR
Intervention: Propofol-midazolam combination
Number of subjects: 150
Study 7482079 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy (SRT) at 3-4 hours after birth
Number of subjects: 78
Study 7482079 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy (SRT) at 6-8 hours after birth
Number of subjects: 78
Study 7482079 — intervention group
Group type: COMPARATOR
Intervention: Non-SRT infants (control group)
Number of subjects: 78
Study 7482079 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate HMD infants
Number of subjects: 78
Study 7482079 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe HMD infants
Number of subjects: 78
Study 2345837 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (twice yearly)
Number of subjects: 0
Study 7465348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepafix (disposable instrument)
Number of subjects: 74
Study 7465348 — intervention group
Group type: COMPARATOR
Intervention: Menghini's needle (conventional needle)
Number of subjects: 74
Study 31518424 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 (10 µg/d)
Number of subjects: 91
Study 31518424 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 (15 µg/d)
Number of subjects: 91
Study 31518424 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 (20 µg/d)
Number of subjects: 91
Study 31518424 — intervention group
Group type: COMPARATOR
Intervention: D3 (20 µg/d)
Number of subjects: 91
Study 30476235 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) trial only
Number of subjects: 198
Study 30476235 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS implanted permanently
Number of subjects: 198
Study 30476235 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS implanted but later explanted
Number of subjects: 198
Study 30476235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 30476235 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS trial only vs. permanent SCS
Number of subjects: 198
Study 28957970 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage for 10 minutes five times a week for 4 weeks, plus toilet/diet/motivation training for parents (30 minutes once per week for 4 weeks).
Number of subjects: 37
Study 28957970 — intervention group
Group type: COMPARATOR
Intervention: Control group received equivalent toilet/diet/motivation training only (30 minutes once per week for 4 weeks).
Number of subjects: 37
Study 26432181 — intervention group
Group type: EXPERIMENTAL
Intervention: TEV-48125 675/225 mg
Number of subjects: 264
Study 26432181 — intervention group
Group type: EXPERIMENTAL
Intervention: TEV-48125 900 mg
Number of subjects: 264
Study 26432181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 24224471 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-OX40L monoclonal antibody (MAb)
Number of subjects: 28
Study 24224471 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 24224471 — intervention group
Group type: COMPARATOR
Intervention: anti-OX40L monoclonal antibody (MAb) and placebo
Number of subjects: 28
Study 21833849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless technique with partially absorbable mesh and fibrin glue
Number of subjects: 148
Study 21833849 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique with non-absorbable mesh and suture
Number of subjects: 148
Study 20871453 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with embolization
Number of subjects: 40
Study 20871453 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) alone
Number of subjects: 40
Study 20871453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernous carotid fistulas
Number of subjects: 40
Study 17023874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (increased levels)
Number of subjects: 485
Study 17023874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (increased levels) in non-HT users
Number of subjects: 485
Study 17023874 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) users
Number of subjects: 485
Study 17023874 — intervention group
Group type: COMPARATOR
Intervention: Non-hormone therapy (non-HT) users
Number of subjects: 485
Study 15863490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (5 seconds)
Number of subjects: 52
Study 15863490 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung inflation (2 seconds)
Number of subjects: 52
Study 11980938 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine
Number of subjects: 12692
Study 11980938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tincture of iodine
Number of subjects: 12692
Study 11980938 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Number of subjects: 12692
Study 11980938 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine with 70% ethyl alcohol (Persist)
Number of subjects: 12692
Study 11980938 — intervention group
Group type: COMPARATOR
Intervention: Previous 12-month period (control)
Number of subjects: 12692
Study 10210789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monotherapy
Number of subjects: 37
Study 10210789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 37
Study 10210789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment methods
Number of subjects: 37
Study 10210789 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 37
Study 8675066 — intervention group
Group type: EXPERIMENTAL
Intervention: EPH gestosis group
Number of subjects: 70
Study 8675066 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant women group
Number of subjects: 70
Study 1983499 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic therapy with clomethiazol and haloperidol (group 1)
Number of subjects: 50
Study 1983499 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ethanol infusions (2‐4 g/h) postoperatively as prophylaxis for WS (group 2)
Number of subjects: 50
Study 7073790 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 0.125 g/kg body weight
Number of subjects: 0
Study 7073790 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 0.25 g/kg body weight
Number of subjects: 0
Study 31615336 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional TA training as described by Ericsson and Simon
Number of subjects: 20
Study 31615336 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific TA training
Number of subjects: 20
Study 31311018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion hemodiafiltration (I-HDF)
Number of subjects: 70
Study 31311018 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 70
Study 29075917 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational treatment strategy
Number of subjects: 528
Study 29075917 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment strategy
Number of subjects: 528
Study 25704072 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen EPIT (n = 48)
Number of subjects: 98
Study 25704072 — intervention group
Group type: COMPARATOR
Intervention: Placebo EPIT (n = 50)
Number of subjects: 98
Study 25704072 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen EPIT
Number of subjects: 98
Study 25534747 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 900 mg loading dose on Day 1, followed by 600 mg/day from Day 2 to 9
Number of subjects: 34
Study 25534747 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 34
Study 21134450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) co-administered
Number of subjects: 1341
Study 21134450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) administered sequentially one month apart
Number of subjects: 1341
Study 19939445 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care
Number of subjects: 1453
Study 19939445 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care
Number of subjects: 1453
Study 19758646 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 gm soy protein containing 160 mg total isoflavones
Number of subjects: 33
Study 19758646 — intervention group
Group type: COMPARATOR
Intervention: 20 gm whole milk protein (placebo)
Number of subjects: 33
Study 16382590 — intervention group
Group type: EXPERIMENTAL
Intervention: LED curing light (fast curing mode)
Number of subjects: 40
Study 16382590 — intervention group
Group type: EXPERIMENTAL
Intervention: LED curing light (pulse curing mode)
Number of subjects: 40
Study 16382590 — intervention group
Group type: EXPERIMENTAL
Intervention: LED curing light (stepped curing mode)
Number of subjects: 40
Study 16382590 — intervention group
Group type: COMPARATOR
Intervention: Visible curing light
Number of subjects: 40
Study 16382590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vickers hardness test
Number of subjects: 40
Study 11978848 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 40
Study 11978848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizygotic co-twins discordant for schizophrenia
Number of subjects: 40
Study 11978848 — intervention group
Group type: EXPERIMENTAL
Intervention: Monozygotic co-twins of schizophrenia probands
Number of subjects: 40
Study 11978848 — intervention group
Group type: COMPARATOR
Intervention: Healthy control twins
Number of subjects: 40
Study 11978848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral and third ventricle enlargements
Number of subjects: 40
Study 9397059 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep Pap test
Number of subjects: 35560
Study 7955966 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT scanning in asbestos-exposed workers
Number of subjects: 70
Study 3655274 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 32
Study 3655274 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration-Intensity-Behavior Scale (DIBS)
Number of subjects: 32
Study 12510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (up to 1.2 g daily)
Number of subjects: 2815
Study 12510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (up to 3 g daily)
Number of subjects: 2815
Study 12510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 3 g daily)
Number of subjects: 2815
Study 12510944 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 2815
Study 12510944 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 2815
Study 29254399 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 9950
Study 29254399 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9950
Study 29254399 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening (age 55-59)
Number of subjects: 9950
Study 29254399 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening (low education)
Number of subjects: 9950
Study 26892284 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 315
Study 26892284 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 315
Study 26892284 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐treatment infarct volume
Number of subjects: 315
Study 26892284 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta National Institute of Health Stroke Scale
Number of subjects: 315
Study 23848177 — intervention group
Group type: EXPERIMENTAL
Intervention: Navarakizhi
Number of subjects: 18
Study 23848177 — intervention group
Group type: COMPARATOR
Intervention: Pinda sweda
Number of subjects: 18
Study 22339556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine artery ligation with nerve resection (group A)
Number of subjects: 60
Study 22339556 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic surgery without sphenopalatine artery ligation (group B)
Number of subjects: 60
Study 22339556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 60
Study 20659517 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg hemagglutinin antigen
Number of subjects: 107
Study 20659517 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg hemagglutinin antigen
Number of subjects: 107
Study 18520587 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-echo-planar diffusion-weighted MRI
Number of subjects: 32
Study 18520587 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 15824943 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed antireflux stent
Number of subjects: 36
Study 15824943 — intervention group
Group type: COMPARATOR
Intervention: Dostent
Number of subjects: 36
Study 15824943 — intervention group
Group type: COMPARATOR
Intervention: Standard open stent
Number of subjects: 36
Study 12439773 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month jumping intervention (trainees, N = 50)
Number of subjects: 99
Study 12439773 — intervention group
Group type: COMPARATOR
Intervention: Control group (controls, N = 49)
Number of subjects: 99
Study 12439773 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femur BMC accrual (trainees, N = 50)
Number of subjects: 99
Study 10338219 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (Genotropin; Pharmacia Ltd, Uppsala, Sweden) 0.3 IU/kg/d for 6 days before and after surgery
Number of subjects: 33
Study 10338219 — intervention group
Group type: COMPARATOR
Intervention: rhGH (Genotropin; Pharmacia Ltd, Uppsala, Sweden) 0.3 IU/kg/d for 6 days after surgery
Number of subjects: 33
Study 10338219 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 days before and after surgery
Number of subjects: 33
Study 7796057 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.17-0.34- or 0.51-M sucrose solution (2 ml)
Number of subjects: 72
Study 7796057 — intervention group
Group type: COMPARATOR
Intervention: Water (2 ml)
Number of subjects: 72
Study 2019145 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular port cardiac output measurements
Number of subjects: 47
Study 2019145 — intervention group
Group type: COMPARATOR
Intervention: Central venous port cardiac output measurements
Number of subjects: 47
Study 2019145 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular port cardiac output measurements in catheters located in the right ventricle
Number of subjects: 47
Study 6963074 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraamniotic PGF2 alpha
Number of subjects: 100
Study 6963074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PGE2
Number of subjects: 100
Study 6963074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sulprostone (2 schedules)
Number of subjects: 100
Study 6963074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular sulprostone (2 schedules)
Number of subjects: 100
Study 30933354 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line platinum-based chemotherapy (carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel)
Number of subjects: 959
Study 30933354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 1 (Q1) with >0% to 25% tumor reduction
Number of subjects: 959
Study 30933354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 2 (Q2) with >25% to 50% tumor reduction
Number of subjects: 959
Study 30933354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 3 (Q3) with >50% to 75% tumor reduction
Number of subjects: 959
Study 30933354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (Q4) with >75% tumor reduction
Number of subjects: 959
Study 30933354 — intervention group
Group type: COMPARATOR
Intervention: No tumor reduction (NTR)
Number of subjects: 959
Study 27742412 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 0
Study 27742412 — intervention group
Group type: COMPARATOR
Intervention: No headache
Number of subjects: 0
Study 28053292 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E® (PolyE®) containing 200 mg EGCG administered with food, BID
Number of subjects: 97
Study 28053292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 25056277 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg of 0.75% intrathecal hyperbaric bupivacaine
Number of subjects: 50
Study 25056277 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.0 mg of 0.75% intrathecal hyperbaric bupivacaine
Number of subjects: 50
Study 22059803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (N = 72)
Number of subjects: 146
Study 22059803 — intervention group
Group type: COMPARATOR
Intervention: Orlistat plus low-fat diet (N = 74)
Number of subjects: 146
Study 19856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 35
Study 19856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado-soybean unsaponifiables
Number of subjects: 35
Study 19856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal mixture SKI306X
Number of subjects: 35
Study 19856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Devil's claw
Number of subjects: 35
Study 19856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder from rose hip and seed
Number of subjects: 35
Study 19856319 — intervention group
Group type: COMPARATOR
Intervention: Willow bark extract
Number of subjects: 35
Study 19856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytodolor NR
Number of subjects: 35
Study 17995656 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirectly puffed snacks produced with 30%, 40%, 50% peanut flour at various screw speeds and feed rates
Number of subjects: 0
Study 17995656 — intervention group
Group type: EXPERIMENTAL
Intervention: Product extruded with 50% peanut flour at screw speed of 400 rpm and feed rate of 6 kg/h
Number of subjects: 0
Study 17995656 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted regression models
Number of subjects: 0
Study 17995656 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum region identified for consumer attributes
Number of subjects: 0
Study 16377601 — intervention group
Group type: COMPARATOR
Intervention: Single Untailored (SU) group - one untailored set of materials
Number of subjects: 3402
Study 16377601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Tailored (MT) group - four tailored materials
Number of subjects: 3402
Study 16377601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Retailored (MRT) group - four tailored materials with retailoring
Number of subjects: 3402
Study 16377601 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Tailored (ST) group - one tailored booklet
Number of subjects: 3402
Study 16377601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Tailored (MT) group
Number of subjects: 3402
Study 11533291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and resistance training
Number of subjects: 98
Study 11533291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 98
Study 11533291 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98
Study 11533291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation or training)
Number of subjects: 98
Study 9604192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandaging (group A)
Number of subjects: 40
Study 9604192 — intervention group
Group type: COMPARATOR
Intervention: Bracing (group B)
Number of subjects: 40
Study 7790748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch ePTFE (Gore‐Tex) prosthesis
Number of subjects: 379
Study 7790748 — intervention group
Group type: COMPARATOR
Intervention: Dacron (Unigraft, Braun‐Melsungen) grafts
Number of subjects: 379
Study 3132054 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 31
Study 3132054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31951273 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 166
Study 31951273 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous pinning
Number of subjects: 166
Study 31951273 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 166
Study 31951273 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (casts)
Number of subjects: 166
Study 31951273 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 166
Study 30170305 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA-creatine mixture (1 gram of GAA and 3 grams of creatine per day)
Number of subjects: 14
Study 30170305 — intervention group
Group type: COMPARATOR
Intervention: Creatine alone (4 grams per day)
Number of subjects: 14
Study 28527386 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTall (children with CMT)
Number of subjects: 60
Study 28527386 — intervention group
Group type: COMPARATOR
Intervention: CMTND (no difficulty heel or toe walking)
Number of subjects: 60
Study 28527386 — intervention group
Group type: COMPARATOR
Intervention: CMTDH (difficulty heel walking)
Number of subjects: 60
Study 28527386 — intervention group
Group type: COMPARATOR
Intervention: CMTDTH (difficulty toe and heel walking)
Number of subjects: 60
Study 26583657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue (Histoacryl)
Number of subjects: 625
Study 26583657 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping mesh (Parietex ProGrip)
Number of subjects: 625
Study 26583657 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonabsorbable sutures (Prolene 2-0)
Number of subjects: 625
Study 26583657 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 625
Study 23548511 — intervention group
Group type: EXPERIMENTAL
Intervention: Defatted milk (0.5%)
Number of subjects: 165
Study 23548511 — intervention group
Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 165